| Phenylbutyrate/Genistein Duotherapy in Delta F508-Homozygous(for Cystic Fibrosis) (NCT00016744) | Children's Hospital of Philadelphia | 2001-09-01 |
| Early Diagnosis of Diabetes Mellitus in Patients With Cystic Fibrosis (NCT00662714) | Mukoviszidose Institut gGmbH | 2001-09-01 |
| Gene Modifiers of Cystic Fibrosis Lung Disease (NCT00037765) | University of North Carolina, Chapel Hill | 2001-09-01 |
| Genetic Modifiers of Cystic Fibrosis: Sibling Study (NCT00037778) | Johns Hopkins University | 2001-09-01 |
| Comparison of 2 Treatment Regimens for Eradication of P Aeruginosa Infection in Children With Cystic Fibrosis (NCT01400750) | Universitaire Ziekenhuizen KU Leuven | 2001-08-01 |
| Efficacy of Amiloride and Hypertonic Saline in Cystic Fibrosis (NCT00274391) | University of North Carolina | 2001-07-01 |
| The Role of Bacteria and Genetic Variations in Cystic Fibrosis (NCT00043225) | National Heart, Lung, and Blood Institute (NHLBI) | 2001-06-20 |
| A Study in Adult and Pediatric Patients With Cystic Fibrosis (NCT00034515) | Merck Sharp & Dohme LLC | 2001-06-01 |
| Diabetes Therapy to Improve BMI and Lung Function in CF (NCT00072904) | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 2001-06-01 |
| Tissue Collection From People With Cystic Fibrosis (NCT00015756) | National Heart, Lung, and Blood Institute (NHLBI) | 2001-05-02 |
| Cystic Fibrosis Withdrawal of Inhaled Steroids Evaluation Study (CF WISE Study) (NCT00220259) | Royal Brompton & Harefield NHS Foundation Trust | 2001-05-01 |
| Assessment of Response to Treatment of Osteoporosis With Oral Bisphosphonates in Patients With Muscular Dystrophy (NCT01882400) | Gilles Boire | 2001-05-01 |
| Interferon Gamma-1b by Inhalation for the Treatment of Patients With Cystic Fibrosis (NCT00043316) | InterMune | 2001-02-01 |
| Phase II Study of Growth Hormone in Children With Cystic Fibrosis (NCT00016445) | University of Utah | 2001-02-01 |
| Study of Metabolic Effects of Pregnancy in Women With Cystic Fibrosis (NCT00014768) | National Center for Research Resources (NCRR) | 2001-02-01 |
| The Prevalence and Significance of Gastro-oesophageal Reflux in Cystic Fibrosis Before and After Lung Transplantation (NCT00164021) | Bayside Health | 2001-02-01 |
| Study of Hepatic Glucose Production and De Novo Lipogenesis in Patients With Cystic Fibrosis (NCT00014781) | University of Utah | 2001-02-01 |
| Macrolide Antibiotic Therapy for Patients With Cystic Fibrosis (NCT00205634) | Wake Forest University | 2000-12-01 |
| Effects of a 6-Months Physical Conditioning Program in Patients With Cystic Fibrosis (NCT00231686) | Julius-Maximilians University | 2000-11-01 |
| The Effects of Long Term Inhalation of Hypertonic Saline in Subjects With Cystic Fibrosis (NCT00271310) | Royal Prince Alfred Hospital, Sydney, Australia | 2000-09-01 |
| A Study of the Safety and Efficacy of Tobramycin for Inhalation in Young Children With Cystic Fibrosis (NCT00006280) | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 2000-02-01 |
| Growth Hormone Treatment Study in Children With Cystic Fibrosis (NCT00256555) | University of Texas Southwestern Medical Center | 2000-02-01 |
| Airway Secretion Clearance in Cystic Fibrosis (NCT00839644) | University of Colorado, Denver | 1999-12-01 |
| A Study to Determine the Variability of a 6-Minute Walk Test in Cystic Fibrosis Subjects With Advanced Lung Disease (NCT00311506) | Genentech, Inc. | 1999-10-01 |
| Phase I Randomized Study of Adeno-Associated Virus-CFTR Vector in Patients With Cystic Fibrosis (NCT00004533) | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 1999-08-01 |
| Randomized Study of Pancrelipase With Bicarbonate (PANCRECARB) Capsules in Reducing Steatorrhea in Patients With Cystic Fibrosis (NCT00006063) | National Center for Research Resources (NCRR) | 1999-07-01 |
| Should Any One Airway Clearance Technique be Recommended for People With Cystic Fibrosis? (NCT00890370) | Royal Brompton & Harefield NHS Foundation Trust | 1999-07-01 |
| Tissue Bank for Pulmonary Diseases (NCT00546962) | Boston Children's Hospital | 1999-04-01 |
| Randomized Study of Alendronate in Adult Patients With Cystic Fibrosis Related Osteoporosis (NCT00004489) | University of North Carolina | 1998-10-01 |
| Role of Toxins in Lung Infections Caused by Pseudomonas Aeruginosa (NCT00027183) | National Heart, Lung, and Blood Institute (NHLBI) | 1998-03-17 |
| Study of Tauroursodeoxycholic Acid for Hepatobiliary Disease in Cystic Fibrosis (NCT00004441) | Children's Hospital Medical Center, Cincinnati | 1997-09-01 |
| Phase I Randomized Study of CPX for the Treatment of Adult Patients With Mild Cystic Fibrosis (NCT00004428) | FDA Office of Orphan Products Development | 1997-09-01 |
| Role of Genetic Factors in the Development of Lung Disease (NCT00001532) | National Heart, Lung, and Blood Institute (NHLBI) | 1996-09-13 |
| Study of Uridine Triphosphate (UTP) as an Aerosol Spray for Cystic Fibrosis (NCT00004705) | FDA Office of Orphan Products Development | 1996-09-01 |
| Study of Ibuprofen to Preserve Lung Function in Patients With Cystic Fibrosis (NCT00004440) | FDA Office of Orphan Products Development | 1996-08-01 |
| Behavioral Treatment of Weight Gain in CF (NCT00006169) | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 1996-06-01 |
| Study of Total Energy Expenditure in Infants and Children With Moderate to Severe Cystic Fibrosis (NCT00006273) | National Center for Research Resources (NCRR) | 1996-06-01 |
| Phase II Pilot Study to Compare the Bioavailability of Buffered, Enteric-Coated Ursodiol With Unmodified Ursodiol for Chronic Cholestatic Liver Disease and Cystic Fibrosis-Associated Liver Disease (NCT00004315) | National Center for Research Resources (NCRR) | 1995-11-01 |
| Phase I Study of the Third Generation Adenovirus H5.001CBCFTR in Patients With Cystic Fibrosis (NCT00004287) | National Center for Research Resources (NCRR) | 1995-11-01 |
| Multicenter Study of Nontuberculous Mycobacteria in Cystic Fibrosis Patients (NCT00004296) | National Center for Research Resources (NCRR) | 1995-09-01 |
| Phase I Pilot Study of Gene Therapy for Cystic Fibrosis Using Cationic Liposome Mediated Gene Transfer (NCT00004471) | University of Alabama at Birmingham | 1995-08-01 |
| Phase II Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Mucoid Exopolysaccharide Pseudomonas Aeruginosa Immune Globulin for Cystic Fibrosis (NCT00004747) | National Center for Research Resources (NCRR) | 1995-07-01 |
| Phase III Randomized Study of the Inhalation of Tobramycin in Patients With Cystic Fibrosis (NCT00004829) | FDA Office of Orphan Products Development | 1995-06-01 |
| Phase I Study of Liposome-Mediated Gene Transfer in Patients With Cystic Fibrosis (NCT00004806) | University of Alabama at Birmingham | 1995-06-01 |
| Phase I Pilot Study of Ad5-CB-CFTR, an Adenovirus Vector Containing the Cystic Fibrosis Transmembrane Conductance Regulator Gene, in Patients With Cystic Fibrosis (NCT00004779) | National Center for Research Resources (NCRR) | 1993-01-01 |
| Prediction of Survival in Children With Cystic Fibrosis Using the Multiple-breath Washout (NCT04016194) | Insel Gruppe AG, University Hospital Bern | 1990-01-01 |
| Diagnosis and Treatment of Patients With Cystic Fibrosis (NCT00001223) | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 1988-01-01 |
| Benefits and Risks of Newborn Screening for Cystic Fibrosis (NCT00014950) | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | |
| Study to Evaluate Arikace™ in CF Patients With Chronic Infection Due to Pseudomonas Aeruginosa (NCT01315691) | Insmed Incorporated | |
| Pressure Support Ventilation During CF Exacerbations (NCT00008775) | National Center for Research Resources (NCRR) | |
| VX-445/TEZ/IVA Expanded Access Program for Cystic Fibrosis (CF) Patients Heterozygous for F508del Mutation and a Minimal Function Mutation (F/MF Genotypes) (NCT04058210) | Vertex Pharmaceuticals Incorporated | |
| Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Airway Infection (NCT00499720) | Gilead Sciences | |
| ELX/TEZ/IVA Expanded Access Program for Cystic Fibrosis (CF) Patients With at Least One F508del Mutation (NCT04702360) | Vertex Pharmaceuticals Incorporated | |
| Tezacaftor/Ivacaftor Combination Therapy Expanded Access Program for Patients 12 Years of Age and Older With Cystic Fibrosis (NCT03278314) | Vertex Pharmaceuticals Incorporated | |
| Growth Hormone Use in Cystic Fibrosis - a Multicenter Study (NCT00005112) | National Center for Research Resources (NCRR) | |
| A Multi-Centered Study of the Long-Term Effect of Salmeterol and Albuterol in Cystic Fibrosis (NCT00005110) | National Center for Research Resources (NCRR) | |
| Expanded Access Program for Aztreonam Lysine for Inhalation in Canadian Patients With Cystic Fibrosis (NCT00989807) | Gilead Sciences | |
| Bone Health of People With Cystic Fibrosis (NCT00008762) | National Center for Research Resources (NCRR) | |
| VX-770 Expanded Access Program (NCT01381289) | Vertex Pharmaceuticals Incorporated | |
| Quantification of Pulmonary Neutrophil Activity in Cystic Fibrosis Using Radiolabeled Fluorodeoxyglucose and PET Imaging (NCT00023465) | National Center for Research Resources (NCRR) | |